

T

**Walk, Roger A.**

---

**From:** Walk, Roger A.  
**Sent:** Wednesday, January 08, 2003 3:01 PM  
**To:** Schleef, Raymond  
**Cc:** Haussmann, Hans-Juergen; Zhang, Mingda (R&D)  
**Subject:** RE: Update on a project with Kim Janda (Scripps) regarding AGEs

Raymond,

Ein gutes Neues Jahr!

What process to evaluate the proposal and potentially execute a project is being envisaged vis-à-vis the ERP and its processes?

Regards,  
Roger

-----Original Message-----

**From:** Schleef, Raymond  
**Sent:** Wednesday, December 11, 2002 11:27 AM  
**To:** Solana, Rick P.; Haussmann, Hans-Juergen; Patskan, George J.; Roethig, Hans; Podraza, Ken F.; Kobal, Gerd; Holt, Klaus von; Carchman, Loreen; Walk, Roger A.; Dempsey, Ruth; Reininghaus, Wolf; Tricker, Anthony; Davies, Bruce D.; McKinney, Willie J.; Sanders, Edward; Schorp, Matthias; Lemus, Ranulfo; Kuhl, Peter; Schepers, Georg; Melsgen, Thomas; Rustemeier, Klaus; Unverdorben, Martin; Euchenhofer, Christian; Weiler, Horst; 'walntz@msn.com'  
**Subject:** Update on a project with Kim Janda (Scripps) regarding AGEs

Please find attached a proposal by Kim Janda regarding "Normicotine-based aberrant protein glycation". Experiments are proposed to examine many of the topics that we have been discussing including expansion of the project to examine other cigarette smoke-induced glycation products. My initial opinion is that the proposal contains several experiments that should address many of our queries, as well as provide us with new reagents and assay systems. As Kim Janda mentions below, the budget could be trimmed and focused on specific experiments. Please let me know if you have any suggestions or thoughts. Ray Schleef

-----Original Message-----

**From:** Kim D. Janda [SMTP:kdjanda@scripps.edu]  
**Sent:** Wednesday, December 11, 2002 2:09 AM  
**To:** Schleef, Raymond  
**Subject:** Re:Proposal draft

Ray,

Please find enclosed a draft of our proposal to start some collaborative experiments between my lab and Philip Morris. As requested, the proposal is approximately 4 pages long and includes a budget. Please note that the budget has a lot of added "fat"...this contains the usual indirect costs at 88% and an additional 25% which gets tacked on all industrial proposals between TSRI and a outside source. These costs are an institutional policy. We can, however alter the budget when the final experiments are agreed upon....ie remove a scientist, cut back on the supplies or increase both if you have additional experiments you can think of initiating. However, the budget will be the last piece to take place as once we send the proposal through to TSRI and Novartis to pass (the budget) is basically set in stone. Thus, why I am sending all this through now to make necessary changes.

Based on the breadth of many of the experiments and the time necessary to produce monoclonal antibodies, I have designed this as a two-year project. Read the proposal and get in touch with me about any questions and/or comments you have regarding planned experiments, etc. As a reminder, I will have to send this through Novartis and they will have 90 days to pass on it. However, we wanted to ensure the proposal was in its final form from PM's perspective before

submitted to Novartis.

I hope this can serve as a starting point for discussions with your scientific group and we can work something out that benefits everyone. Please get back to me to let me know you received the document.

Kim

---

---

Kim D. Janda  
Professor, Department of Chemistry  
Ely R. Callaway, Jr.  
Chair in Chemistry  
The Scripps Research Institute  
10550 N. Torrey Pines Rd., BCC-582  
La Jolla  
CA92037

Phone: (858)-784 2516

Fax: (858)-784-2595

Admin Asst.: Kay Cole

Phone: (858)-784 2515

e-mail: flash@scripps.edu << File: SFP\_Text\_2.doc >>